Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Neurosense Therapeutics Ltd. ( (NRSN) ) has shared an announcement.
On December 22, 2025, NeuroSense Therapeutics reported that a safety analysis from its proof-of-concept Phase 2, randomized, double-blind, placebo-controlled NST-AD-001 study of PrimeC in Alzheimer’s disease showed a favorable tolerability profile, with no serious adverse events and no new or unexpected safety signals. As an exploratory trial, the clinical outcome measures are descriptive, and the company plans to interpret these clinical observations together with biomarker data, with combined clinical and biomarker results expected in the first quarter of 2026, potentially informing PrimeC’s future development path and NeuroSense’s positioning in the competitive Alzheimer’s drug development landscape.
The most recent analyst rating on (NRSN) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Neurosense Therapeutics Ltd. stock, see the NRSN Stock Forecast page.
Spark’s Take on NRSN Stock
According to Spark, TipRanks’ AI Analyst, NRSN is a Underperform.
Neurosense Therapeutics Ltd. faces substantial financial difficulties, including no revenue and negative equity, severely impacting its overall score. Technical indicators are neutral but do not offset financial weaknesses. The valuation is unattractive due to negative earnings and no dividend yield.
To see Spark’s full report on NRSN stock, click here.
More about Neurosense Therapeutics Ltd.
NeuroSense Therapeutics Ltd. is a late-clinical-stage biotechnology company focused on discovering and developing combination therapies for debilitating neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and Parkinson’s disease. Its lead candidate, PrimeC, is an extended-release oral fixed-dose combination of the FDA-approved drugs ciprofloxacin and celecoxib, designed to target multiple disease mechanisms such as neuron degeneration, inflammation, iron accumulation and impaired RNA regulation, addressing significant unmet needs where current treatments offer only limited symptomatic relief.
Average Trading Volume: 311,047
Technical Sentiment Signal: Sell
Current Market Cap: $24.06M
See more data about NRSN stock on TipRanks’ Stock Analysis page.